Literature DB >> 27801317

[The clinical features, cytogenetic characteristics and survival analysis of 550 myelodysplastic syndromes in a single center].

T T Zhang1, A N Sun, J L Pan, D P Wu, H Y Qiu, X W Tang, M Miao, S N Chen.   

Abstract

Objective: To retrospectively analyze the clinical features, cytogenetic characteristics and survival of 550 newly diagnosed myelodysplastic syndrome(MDS)patients. Method: By using WHO(2008)criterion for classification, the prognosis of stratification of 550 patients were evaluated according to the IPSS/WPSS/IPSS-R.
Results: The median age was 57 years old(range: 12-89 years old). The ratio of male and female was 1.72. In all patients, the median hemoglobin level was 72(22-154)g/L, the median platelet count was 52(3-587)×109/L and the median WBC was 2.52(0.11-48.00)×109/L. 45.6%(251/550)patients had clonal chromosome abnormalities, in which 89(16.2%)patients with complex karyotype. The types of chromosome aberration were mainly dominated by unbalanced anomalies, and the most common types of chromosome aberration were trisomy or monosomy. The most common abnormity was +8. Other aberrations in frequent order were - 7/del(7q), del(5q), del(20q), and so on. In addition, 550 patients were evaluated according to IPSS, IPSS-R, and WPSS prognostic scoring system. The results showed that the IPSS, WPSS and IPSS-R scores were significantly affected OS(P <0.001). The median OS in the IPSSR Low, Intermediate, High and Very Highrisk groups was not reached, 44(95%CI 28-60), 17(95%CI 13- 21)and 8(95%CI 5-11)months, respectively.
Conclusion: In this study, the patients' median age was 57(12- 89)years old, and the cytogenetic characteristics were significantly different from western MDS patients. IPSS, IPSS-R and WPSS were important in predicting the survival of MDS patients.

Entities:  

Mesh:

Year:  2016        PMID: 27801317     DOI: 10.3760/cma.j.issn.0253-2727.2016.10.009

Source DB:  PubMed          Journal:  Zhonghua Xue Ye Xue Za Zhi        ISSN: 0253-2727


  2 in total

1.  [Gene mutations from 511 myelodysplastic syndromes patients performed by targeted gene sequencing].

Authors:  B Li; J Y Wang; J Q Liu; Z X Shi; S L Peng; H J Huang; T J Qin; Z F Xu; Y Zhang; L W Fang; H L Zhang; N B Hu; L J Pan; S Q Qu; Z J Xiao
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-12-14

2.  Clinical significance of cytogenetic and molecular genetic abnormalities in 634 Chinese patients with myelodysplastic syndromes.

Authors:  Xuefen Yan; Lu Wang; Lingxu Jiang; Yingwan Luo; Peipei Lin; Wenli Yang; Yanling Ren; Liya Ma; Xinping Zhou; Chen Mei; Li Ye; Gaixiang Xu; Weilai Xu; Haiyang Yang; Chenxi Lu; Jie Jin; Hongyan Tong
Journal:  Cancer Med       Date:  2021-02-20       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.